3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Esophageal Neoplasms
9
Melanoma
6
Lung Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Hepatocellular
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Carcinoma, Transitional Cell
2
Unresectable Biliary Tract Cancer
1
Thymus Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Small Cell Lung Cancer Extensive Stage
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pathologic Complete Response
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Nasopharyngeal Neoplasms
1
Muscle-Invasive Bladder Carcinoma
1
Interventions
pembrolizumab
6
cabozantinib
6
Nivolumab
5
Ipilimumab
5
Axitinib
5
Radiosurgery
3
Blood Specimen Collection
3
zimberelimab
2
lenvatinib
2
Ultrasonography
2
Radiotherapy
2
Biopsy
2
tislelizumab
1
polyethylene glycol 3350
1
pazopanib
1
palbociclib
1
orellanine
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
cyclopropapyrroloindole
1
brodalumab
1
belzutifan
1
atezolizumab
1
anlotinib
1
adagrasib
1
Watchful Waiting
1
Vincristine
1
Therapeutics
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Kidney Neoplasms
×
Immunotherapy
×
Clear all
NCT06583070
2026-01-28
COSTAR
Peking University First Hospital
Recruiting
300 enrolled